“Further to our intimation dated May 25, 2017 with regard to the audit of our Formulation Srikakulam Plant (SEZ) Unit II, Andhra Pradesh, we would now like to inform you that we have received an Establishment Inspection Report (EIR) from the USFDA, for the above-referred facility,” said the company in a BSE filing on Thursday.
The stock of pharma major Dr Reddy’s, was buzzing on the bourses as it was trading up by over 5% on the BSE. It was trading at Rs 2443.05 per share, up by Rs 129.45 or 5.60% as at 1014 hours on Thursday, on the BSE.
The stock attracted a traded volume of 13,99,521 shares and traded value of Rs 33,782.48 lakh on the NSE.
Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products.
Looking for investment in Share Market, CapitalStars Financial Research Private Limited provides you best investments Tips in Share Market.It daily provides intraday and Future calls.We generate intraday as well as delivery calls in Stock cash and F&O in NSE & BSE, Commodities.
Get more details here:-
* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
* CapitalStars Investment Adviser: SEBI Registration Number: INA000001647
0 comments:
Post a Comment